Fluoroarabino nucleic acid aptamers for blocking SARS-CoV-2 spike binding to ACE2
Fluoroarabino nucleic acid aptamers block the SARS-CoV-2 spike protein’s binding to ACE2, acting as antiviral agents to prevent and treat COVID-19.
Background
The rapid spread of respiratory viruses like SARS-CoV-2 has underscored the critical need for agents that prevent the virus from entering human cells. Infection begins when the viral spike protein binds to the ACE2 receptor on the surface of lung and airway cells, which triggers viral entry and replication. Although vaccines have greatly reduced severe illness, there remains a significant demand for treatments that can block this initial binding step—especially for people who are unvaccinated, immunocompromised, or exposed to new viral variants. A readily available therapy that halts infection at the earliest stage could curb transmission and reduce the burden on healthcare systems.
Current strategies to block viral entry include monoclonal antibodies and small-molecule drugs, but both approaches face limitations. Monoclonal antibodies often require intravenous administration in a clinical setting, stringent refrigeration, and high production costs, making them difficult to deploy widely. Moreover, viral mutations in the spike protein can render these antibodies less effective over time. Small-molecule antivirals typically target enzymes active after the virus has entered the cell, so they are less useful for prevention. Together, these challenges highlight a clear gap for a stable, cost-effective, easily administered entry inhibitor that remains potent against evolving viral strains.
Technology
Fluoroarabino nucleic acid (FANA) aptamers are synthetic, single-stranded molecules built from modified nucleic acid building blocks that fold into precise three-dimensional shapes. These structures enable them to bind tightly and specifically to the receptor binding domain of the SARS-CoV-2 spike protein. By occupying the same surface that the virus uses to attach to the human angiotensin-converting enzyme 2 (ACE2) receptor, they effectively block entry of the virus into host cells. The fluoroarabino modification strengthens the backbone against enzymatic breakdown, while the small, well-defined size supports predictable tissue distribution. Formulations can be designed for intravenous injection or inhalation, offering flexible options for both treatment and prevention of COVID-19.
What sets this technology apart is its combination of strong, specific binding and exceptional chemical stability. Unlike natural DNA or RNA sequences, these modified aptamers resist degradation in biological fluids, extending their active lifespan. They can be produced entirely by chemical synthesis, avoiding the complexity and cost of cell-based protein manufacturing. Their compact size also reduces the chance of triggering unwanted immune responses. Finally, the aptamer sequences can be rapidly adjusted to match new viral variants, providing a faster development path and scalable production compared with traditional antibody therapies or small-molecule antivirals.
Benefits
- Blocks SARS-CoV-2 spike protein from binding ACE2, directly preventing viral entry
- High specificity for the receptor binding domain minimizes off-target interactions
- Fluoroarabino nucleic acid backbone confers enhanced stability and nuclease resistance
- Suitable for both therapeutic treatment and prophylactic use against COVID-19
- Chemical synthesis allows rapid, scalable, and cost-effective production
- Low immunogenicity reduces the risk of adverse immune responses
Applications
- COVID-19 antiviral therapy
- Prophylactic nasal spray
- Inhalable antiviral aerosol
- Therapeutic injectable formulation
Additional info
Fluoroarabino nucleic acid aptamers are synthetic oligonucleotides incorporating 2′-fluoroarabinose modifications, designed to bind the SARS-CoV-2 spike protein receptor-binding domain with high affinity, sterically blocking ACE2 engagement. Their nuclease resistance and specificity enables therapeutic application as antiviral agents for COVID-19 prophylaxis and treatment.